Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study
Shi HJ, Song H, Zhao QY, Tao CX, Liu M, Zhu QQ
Medicine · 16 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Ningxia University
- Universidad u hospital
- Ningxia Medical University
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2018-09-01 · Medicine (Baltimore) · vol. 97 · número 37 · pág. e12398
- Editorial
- Wolters Kluwer
- Citado
- 23 citas · más que el 77% de estudios similares · 1.1× el promedio de su campo
- Referencias
- 56 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-ND
- Áreas de investigación
- Cervical Cancer and HPV Research · Laser Applications in Dentistry and Medicine · Reproductive tract infections research
- Palabras clave
- Medicine, Cervicitis, Vaginitis, Human papillomavirus, Gynecology, Internal medicine
- MeSH
- humans, papillomaviridae, papillomavirus infections, vaginitis, interferon-alpha, recombinant proteins, antiviral agents, treatment outcome, combined modality therapy, phototherapy, prospective studies, single-blind method, adolescent, adult, middle aged, uterine cervicitis, female, young adult, interferon alpha-2
6 autores
- Huijuan Shi🇨🇳 · autor de correspondenciaNingxia Medical University; Ningxia Medical University General Hospital
- Hongbin Song🇨🇳Chinese PLA General Hospital
- Qianying Zhao🇨🇳Ningxia Medical University; Ningxia Medical University General Hospital
- Chun-Xia Tao🇨🇳Ningxia Hui Autonomous Region Peoples Hospital
- Min Liu🇨🇳Ningxia Medical University; Ningxia Medical University General Hospital
- Qin-Qin Zhu🇨🇳Ningxia Hui Autonomous Region Peoples Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
We evaluated the efficacy and safety of combined high-dose interferon (IFN) and red light therapy for the treatment of subclinical and latent human papillomavirus (HPV) infections.
Methods
Ninety women diagnosed with subclinical or latent HPV infection were randomized to receive topical application of low-dose recombinant IFNα-2b (1 million IU), high-dose IFNα-2b (9 million IU), or a combination of high-dose IFNα-2b and red light therapy on the cervix and vagina. All patients received treatment once daily for 4 weeks. HPV titer was measured immediately and 4, 8, and 12 weeks after treatment to determine the rates of viral clearance and infection cure. Treatment of HPV-associated vaginitis and cervicitis was also evaluated.
Results
Results showed that immediately and 4, 8, and 12 weeks after treatment, the HPV clearance rates and infection cure rates were higher in the high-dose IFN and combination groups compared to the low-dose IFN group. High-dose IFN and combination therapies were significantly effective against both low-risk and high-risk HPV infections. Although the cure rates for vaginitis and cervicitis were significantly higher in the high- compared to the low-dose IFN group, rates were even higher in the combination group compared to the high-dose IFN group. Mild adverse effects were reported by a very small subset of patients (3/30) in the combination group.
Conclusions
This study suggests that combination of high-dose IFN and red light therapy is safe and effective against subclinical and latent HPV infections.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.